Reviewing Voyager Therapeutics Inc. (VYGR)’s and Apellis Pharmaceuticals Inc. (NASDAQ:APLS)’s results

This is therefore a comparing of the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation in Voyager Therapeutics Inc. (NASDAQ:VYGR) and Apellis Pharmaceuticals Inc. (NASDAQ:APLS). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Voyager Therapeutics Inc. 22 11.16 N/A -2.94 0.00
Apellis Pharmaceuticals Inc. 23 0.00 N/A -2.77 0.00

In table 1 we can see Voyager Therapeutics Inc. and Apellis Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows us Voyager Therapeutics Inc. and Apellis Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Voyager Therapeutics Inc. 0.00% -129.7% -38.2%
Apellis Pharmaceuticals Inc. 0.00% -77.1% -60.8%


The Current Ratio and Quick Ratio of Voyager Therapeutics Inc. are 6.2 and 6.2 respectively. Its competitor Apellis Pharmaceuticals Inc.’s Current Ratio is 15.2 and its Quick Ratio is 15.2. Apellis Pharmaceuticals Inc. can pay off short and long-term obligations better than Voyager Therapeutics Inc.

Analyst Recommendations

Voyager Therapeutics Inc. and Apellis Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Voyager Therapeutics Inc. 0 0 0 0.00
Apellis Pharmaceuticals Inc. 0 0 1 3.00

Voyager Therapeutics Inc.’s consensus target price is $21, while its potential upside is 22.16%. Apellis Pharmaceuticals Inc. on the other hand boasts of a $45 consensus target price and a 66.67% potential upside. Based on the data given earlier, Apellis Pharmaceuticals Inc. is looking more favorable than Voyager Therapeutics Inc., analysts opinion.

Institutional and Insider Ownership

Roughly 75.6% of Voyager Therapeutics Inc. shares are owned by institutional investors while 66.1% of Apellis Pharmaceuticals Inc. are owned by institutional investors. About 11.5% of Voyager Therapeutics Inc.’s share are owned by insiders. Comparatively, 1.6% are Apellis Pharmaceuticals Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Voyager Therapeutics Inc. -7.37% -21.17% 5.56% 109.22% 20.47% 134.15%
Apellis Pharmaceuticals Inc. -3.62% 9.83% 49.36% 105.82% 57.53% 111.75%

For the past year Voyager Therapeutics Inc. has stronger performance than Apellis Pharmaceuticals Inc.


Apellis Pharmaceuticals Inc. beats on 6 of the 9 factors Voyager Therapeutics Inc.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The companyÂ’s lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for HuntingtonÂ’s disease; VY-FXN01 for Friedreich's ataxia; VY-TAU01, AlzheimerÂ’s disease; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with Genzyme Corporation and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.